diabétologie, nutrition, collection Med-line, pp.237-238, 2001. ,
Pharmacie clinique et thérapeutique, pp.2-387 ,
Physiologie médicale, traduction de la 19ème éditions américaine, De Boeck université édition, 2001, section IV, chapitre 19, pp.318-324 ,
Génétique moléculaire de la résistance à l'insuline et des maladies associées en pathologie humaine cf dossier 1 O. Communiqué de presse conjoint OMS/fédération internationale du diabète, «il faut agir contre le diabète», 2004. ,
Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030, Diabetes Care, vol.27, issue.5, pp.1047-53, 2004. ,
DOI : 10.2337/diacare.27.5.1047
martindale The complete Drug Reference, pp.324-332, 2002. ,
Collin de l'Hortet. Diabète et maladies métaboliques ,
Comment je conseille aux diabétiques insulinodépendants d'adapter leurs doses d'insulines. EQUILIBRE-N°210, pp.19-21, 1999. ,
Diabète insulinodépendant. La revue du Praticien.-vol50, N°13, 1er septembre, pp.1473-1484, 2000. ,
Les échecs des traitements par antidiabétiques oraux. Traité de diabétologie, Edition Pradel, pp.737-777, 1990. ,
New horizons -Alternative routes for insulin therapy UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose contrai with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Nat Rev Drug Discov Lancet, vol.352, issue.17, pp.530-24837, 1998. ,
Totally reimbursed care for type 2 diabetes in 1994: characteristics and follow-up, Diabetes Metab, vol.26, issue.6, pp.55-62, 2000. ,
Programme de santé publique : Diabète de type 2 (Rapport sur la prise en charge des diabétiques exclusivement traités par hypoglycémiants oraux en, p.13, 1998. ,
Managing type 2 diabetes in France: the Ecodia Survey, Diabetes and metabolism, vol.26, pp.363-369, 2000. ,
Role of C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin, Structure, vol.3, issue.6, pp.615-637, 1995. ,
DOI : 10.1016/S0969-2126(01)00195-2
lnsulin therapy in the era of insulin analogs, U.S. Pharmacist, vol.21, pp.35-44, 1996. ,
lnsulin lispro: a fast-acting insulin analog. Am Fam Physician, Jan, vol.15, issue.572, pp.279-86, 1998. ,
Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin, Lys(B28) Diabetes ,
Pro(B29)]-human insulin (K): dose-ranging vs humulin R (H) Diabetes, Lys, 1993. ,
Effect of the Insulin Analogue [LYS(B28),PRO(B29)] on Blood Glucose Control, Hormone and Metabolic Research, vol.26, issue.12, pp.588-90, 1994. ,
DOI : 10.1055/s-2007-1001765
Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment, Diabetes Feb, vol.46, pp.265-70, 1997. ,
Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia i patients with non-insuiin-dependent diabetes mellitus, Arch lntern Med, vol.157, pp.1249-55, 1997. ,
lmproved mealtime treatment of diabetes mellitus using an insulin analogue, Clin Ther, vol.19, issue.1, pp.62-72, 1997. ,
Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes, Experimental and Clinical Endocrinology & Diabetes, vol.104, issue.01, pp.25-30, 1996. ,
DOI : 10.1055/s-0029-1211418
Treatment of 722 patients with type Il diabetes with insulin lispro in a 6 month crossover study, Diabetes, 1995. ,
lmprovement of glycemic contrai with the rapidly absorbed lispro insulin analog in type 1 diabetes, Diabetologia, vol.37, issue.1, p.78, 1994. ,
Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal, Diabetic Medicine, vol.15, issue.7, pp.592-600, 1998. ,
DOI : 10.1002/(SICI)1096-9136(199807)15:7<592::AID-DIA625>3.0.CO;2-J
Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment, Diabetes, vol.46, issue.2, pp.265-70, 1997. ,
DOI : 10.2337/diab.46.2.265
Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime, Diabetes Care, vol.22, issue.3, pp.468-77, 1999. ,
DOI : 10.2337/diacare.22.3.468
Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections, Diabetic Medicine, vol.39, issue.4, pp.319-343, 1999. ,
DOI : 10.1046/j.1464-5491.1999.00077.x
Use of insulin aspart, a fast acting insulin analog, as the meal time insulin in the management of patients with type 1 diabetes, Diabetes Gare, vol.23, pp.583-88, 2000. ,
Insulinothérapie : comment gérer au quotidien les variations physiologiques des besoins en insuline, 1999. ,
Tauber: « Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment », Diabetes care, p.9, 2000. ,
Contribution of postprandial versus interprandial blood gluose to HbA 1 c in type 1 dabetes on physiologie intensive therapy with lispro insulin at mealtime, Diabetes Gare, vol.22, pp.795-800, 1999. ,
lnsulin lispro injection (rDNA origin), 1996. ,
Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin, Lys(B28) Diabetes, 1999. ,
Pharmacokinetics, pharmacodynamies and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue, Pro(B29)] in IDDM. Diabetologia, pp.713-733, 1994. ,
The metabolic efficacy of lispro insulin analogue in a multiple injection (MIT) regimen, Neth J Med, 1995. ,
[Lys(B28), Pro(B29)]-human insulin: Effect of injection time on postprandial glycemia, Clinical Pharmacology & Therapeutics, vol.43, issue.4, pp.459-69, 1995. ,
DOI : 10.1016/0009-9236(95)90060-8
Effect of the Insulin Analogue [LYS(B28),PRO(B29)] on Blood Glucose Control, LYS(B28), pp.588-90, 1994. ,
DOI : 10.1055/s-2007-1001765
lmprovement of glycemic contrai with the rapidly absorbed lispro analog in type 1 diabetes. ln: Abstracts of the 30th annual meeting of the European Association for the Study of Diabetes, Diabetologia, vol.37, p.78, 1994. ,
lnsulin lispro injection (rDNA origin), 1996. ,
Lower within patient variabiliy in postprandial glucose excursion with lispro insulin analog compared with regular insulin, Diabetes, issue.1, p.214, 1995. ,
Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin, Lys(B28) Diabetes ,
Koivisto: « Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes », Diabetes care, p.10, 1998. ,
A core curriculum for diabetes education Chicago: American Association of Diabetes Educators, pp.351-72, 1993. ,
Meta-analysis of the effect of insulin lispro on severe hypoglycaemia patients with type 1 diabetes, Diabet Gare, vol.21, pp.1726-1757, 1998. ,
Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycaemia during intensified insulin therapy, Diabetes Gare, vol.22, pp.1607-1618, 1999. ,
Humalog reduces the incidence of severe hypoglycemia in IDDM patients, Diabetologia, vol.40, issue.1, p.61, 1997. ,
Less nocturnal hypoglycemia with insulin lispro in comparison tu human regular, Diabetes, vol.441, p.111, 1995. ,
lnsulin lispro results in less nocturnal hypoglycemia compared with regular human insulin in adolesents with type 1 dbetes, Diabetes, vol.46, p.103, 1997. ,
Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue, Diabetologia, vol.304, issue.Suppl 1, pp.106-117, 1995. ,
DOI : 10.1007/BF02369359
Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue, Diabetologia, vol.304, issue.Suppl 1, pp.106-117, 1995. ,
DOI : 10.1007/BF02369359
Immunologic Effects of Insulin Lispro [Lys (B28), Pro (B29) Human Insulin] in IDDM and NIDDM Patients Previously Treated With Insulin, Diabetes, vol.45, issue.12, pp.1750-1754, 1996. ,
DOI : 10.2337/diab.45.12.1750
A: lnsulin antibody response ta a short course of human insulin therapy in women with gestational diabetes, Diabetes Gare, vol.20, pp.1172-1175, 1997. ,
Metabolic and immunologie effects of insulin lispro in gestational diabetes, Diabetes Gare, vol.22, pp.1422-1427, 1999. ,
Insulin lispro and regular insulin in pregnancy, QJM, vol.94, issue.5, pp.255-260, 2001. ,
DOI : 10.1093/qjmed/94.5.255
Diabetes Treatment Satisfaction Questionnaire (DTSQ) ln: Bradley C, ed. Handbook of Psychology and Diabetes, pp.111-143, 1994. ,
chemical stability of insulin lispro in insulin infusion system, Diabetes, Abstract book: 55th Annual meeting, 1996. ,
stability of insulin lispro in insulin Infusion System, Diabetes Care, vol.20, p.7, 1997. ,
Use of insulin lispro in continuous subcutaneous insulin infusion treatment" l Diabetes care, p.5, 1999. ,
Neutra! protamine lispro : activity profile of s.c. administration with and without admixture of soluble lispro, Diabetologia, vol.39, issue.1, p.224, 1996. ,
Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients, Diabetes Care, vol.22, issue.5, pp.865-871, 1999. ,
DOI : 10.2337/diacare.22.5.865
Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin, Diabetes Care, vol.21, issue.5, pp.800-803, 1998. ,
DOI : 10.2337/diacare.21.5.800
Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients, Diabetes Care, vol.22, issue.5, pp.865-871, 1999. ,
DOI : 10.2337/diacare.22.5.865
Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients, Diabetes Care, vol.22, issue.3, pp.459-62, 1999. ,
DOI : 10.2337/diacare.22.3.459
Improved postprandial glycemic control with humalog?? mix75/25??? after a standard test meal in patients with type 2 diabetes mellitus, Clinical Therapeutics, vol.22, issue.2, pp.222-252, 2000. ,
DOI : 10.1016/S0149-2918(00)88480-5
Humalog®Mix25 offers better and more consistent mealtime contrai in patients with type 1 and type 2 diabetes than human insulin 30, Diabetes Metab, vol.70, issue.26, pp.481-488, 2000. ,
Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50, Clinical Therapeutics, vol.21, issue.3, pp.523-557, 1999. ,
DOI : 10.1016/S0149-2918(00)88307-1
Reduced nocturnal hypoglycemia with twice daily insulin lispro low mixture compared to human insulin 30/70 in patients with type 2 diabetes, Diabet Med, vol.18, issue.2, p.15, 2001. ,
Improved glucose control following administration of a 75% insulin lispro/25% NPL mixture in patients with type 1 diabetes, Diabetes Research and Clinical Practice, vol.50, issue.1, p.220, 2000. ,
DOI : 10.1016/S0168-8227(00)82209-3
La macroangiopathie. Impact médecin. N°565. 1er février, pp.12-15, 2002. ,
Sel am ,
La rétinopathie diabétique. Impact médecin n° 565, 1er février, pp.4-5, 2002. ,
La néphropathie. Impact médecin. N°565. 1er février, pp.5-6, 2002. ,
La neuropathie diabétique. Impact médecin n° 565, 1er février, pp.7-9, 2002. ,
Le pied diabétique. Impact médecin n° 565, 1er février, pp.9-12, 2002. ,
Contribution of postprandial versus interprandial blood glucose to HbA 1 c in type 1 diabetes on physiologie intensive therapy with iispro insulin at mealtime, Diabetes Gare, vol.22, pp.795-800, 1999. ,
Effects of the short-acting insulin analog [LYS (828),PRO (829)] on postprandial blood glucose contrai in IDDM, Diabetes Gare, vol.19, pp.945-52, 1996. ,
Contribution of postprandial versus interprandial blood glucose to HbA 1 c in type 1 diabetes on physiologie intensive therapy with lispro insulin at mealtime, Diabetes Gare, vol.22, pp.795-800, 1999. ,
lnsulin treatment and its complications. Textbook of diabetes ,
Monomeric insulins and their experimental and clinicat implications, Diabetes Gare, vol.13, pp.923-54, 1990. ,
DOI : 10.2337/diacare.13.9.923
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use, Diabetes, vol.49, issue.6, pp.999-1005, 2000. ,
DOI : 10.2337/diabetes.49.6.999
Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers, European Journal of Clinical Pharmacology, vol.55, issue.3, pp.199-203, 1999. ,
DOI : 10.1007/s002280050618
Time-action Profile of the Insulin Analogue B28Asp, Diabetic Medicine, vol.13, issue.7, pp.683-687, 1996. ,
DOI : 10.1002/(SICI)1096-9136(199607)13:7<683::AID-DIA144>3.0.CO;2-1
Absorption kinetics and action profiles of subcutaneously administered insu lin analogues (Asp829, Glu827, Asp810, AspB28) in healthy subjects, Diabetes Gare, vol.14, pp.1057-65, 1991. ,
Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects, Diabetes Care, vol.22, issue.9, pp.1501-1507, 1999. ,
DOI : 10.2337/diacare.22.9.1501
Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp, Experimental and Clinical Endocrinology & Diabetes, vol.105, issue.03, pp.140-144, 1997. ,
DOI : 10.1055/s-0029-1211742
Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart, Diabetes Care, vol.21, issue.11, pp.1910-1914, 1998. ,
DOI : 10.2337/diacare.21.11.1910
Clinical Pharmacokinetics and Pharmacodynamics of Insulin Aspart, Clinical Pharmacokinetics, vol.17, issue.11, pp.641-59, 2001. ,
DOI : 10.2165/00003088-200140090-00002
Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus, Diabetic Medicine, vol.113, issue.5, pp.371-376, 2000. ,
DOI : 10.1007/s001250051416
Improved postprandial glycaemic controls with insulin Aspart in type 2 diabetic patients treated with insulin, Acta Diabetologica, vol.37, issue.1, pp.41-47, 2000. ,
DOI : 10.1007/s005920070034
Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group, Diabetes Care, vol.21, issue.11, pp.1904-1913, 1998. ,
DOI : 10.2337/diacare.21.11.1904
Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes, Diabetes Care, vol.23, issue.5, pp.583-591, 2000. ,
DOI : 10.2337/diacare.23.5.583
Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial, Diabetic Medicine, vol.21, issue.11, pp.762-70, 2000. ,
DOI : 10.1007/s001250050617
Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin Infusion: A randomized study in type 1 diabetes, Diabetes Care, vol.25, issue.3, pp.439-483, 2002. ,
DOI : 10.2337/diacare.25.3.439
Efficacy, Safety, and Pump Compatibility of Insulin Aspart Used in Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes, Diabetes Care, vol.24, issue.1, pp.69-72, 2001. ,
DOI : 10.2337/diacare.24.1.69
Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart, European Journal of Clinical Pharmacology, vol.56, issue.5, pp.399-403, 2000. ,
DOI : 10.1007/s002280000159
Insulin Aspart in a 30/70 Premixed Formulation: Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture, Diabetes Care, vol.20, issue.10, pp.1612-1616, 1997. ,
DOI : 10.2337/diacare.20.10.1612
Biphasic insulin aspart 30 improves postprandial glycemic contrai, Diabetes, vol.50, issue.2, p.95, 2001. ,
Biphasic insulin aspart and biphasic human insulin compared in type 2 diabetic subjects, Diabetologia, vol.44, issue.1, p.210, 2001. ,
Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus, Clinical Therapeutics, vol.24, issue.4, pp.530-539, 2002. ,
DOI : 10.1016/S0149-2918(02)85129-3
Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes, Metabolism, vol.51, issue.7, pp.896-900, 2002. ,
DOI : 10.1053/meta.2002.33358
Safety and efficacy of long term exposure to biphasic insulin aspart compared with biphasic human 144. New long-acting insulin available, Mayo Clin Health Lett septembre, vol.19, issue.9, p.4, 2001. ,
Basal Insulin Therapy in Type 2 Diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin, Diabetes Care, vol.24, issue.4, pp.631-637, 2001. ,
DOI : 10.2337/diacare.24.4.631
A 16-week comparison of the navel insulin analog insulin glargine (HOE 901) and NPH human insu lin used with insulin lispro in patients with type 1 diabetes, Diabetes Gare novembre, vol.23, issue.11, pp.1666-71, 2000. ,
Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. lnsulin Glargine (HOE 901) Type 1 Diabetes lnvestigator Group, Diabetes Gare août, vol.23, issue.8, pp.1137-1179, 2000. ,
Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites, Diabetes Care, vol.23, issue.6, pp.813-819, 2000. ,
DOI : 10.2337/diacare.23.6.813
lnsulin glargine (HOE901 ): first responsibilities: understanding the data and ensuring safety, Diabetes Gare mai, vol.23, issue.5, pp.576-584, 2000. ,
Applied Therapeutics: The C/inical Use of Drugs ,
DOI : 10.1007/978-1-349-13175-4
American hospital formulary service. Drug information, pp.2988-90, 2001. ,
No evidence for accumulation of insulin glargine (LANTUSR): a multiple injection study in patients with Type 1 diabetes, Diabetic Medicine, vol.42, issue.6, pp.490-495, 2002. ,
DOI : 10.1007/s001250051286
Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes, Annals of Internal Medicine, vol.138, issue.12, pp.952-959, 2003. ,
DOI : 10.7326/0003-4819-138-12-200306170-00006
Morning versus bedtime insulin glargine in combination with glimepiride: no difference in incidence of nocturnal hypoglycemia in patients with type 2 diabetes, Diabetes, vol.52, issue.1, p.574, 2003. ,
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro, Diabetes, vol.49, issue.12, pp.2142-2148, 2000. ,
DOI : 10.2337/diabetes.49.12.2142
Wilson:« efficacy and safety of insulin glargine in subjects with type 1 diabetes: A 28 week randomised, NPH insulin-controlled trial », Diabetes, Abstract book, p.516, 1999. ,
Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes, Diabetes Gare, vol.23, p.2, 2000. ,
Less Hypoglycemia With lnsulin Glargine in Intensive lnsulin Therapy for Type 1 Diabetes, Diabetes Gare, vol.23, p.5, 2000. ,
Less nocturnal hypoglycemia and better post-dinner glucose contrai with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes, Diabetes Gare, vol.23, issue.8, p.1134, 2000. ,
Pharmacodynamies (PD) and Pharmacokinetics (PK) of lnsulin Glulisine Compared with lnsulin Lispro (IL) and Regular Human lnsulin (RHI) in Patients with Type 2 Diabetes, Abstract 503. 64th Annual Scientific Sessions, 2004. ,
Prandial Blood Glucose Contrai with Pre-and Post-Meal lnsulin Glulisine Versus Regular Human lnsulin. Abstract 588, 64th Annual Scientific Sessions, 2004. ,
Efficacy and Safety of Post-Meal lnsulin Glulisine (GLU) Compared with Pre-Meal Regular Human lnsulin (RHI) in a Basal-Bolus Regimen with lnsulin Glargine. Abstract 529, 64th Annual Scientific Sessions, 2004. ,
Ways K lnsulin glulisine provides improved glycemic contrai in patients with type 2 diabetes. Diabetes Gare, pp.2363-2371, 2004. ,
Time-Action Profile of lnsulin Glulisine (GLU) versus Regular Human lnsulin {RHI) and lnsulin Lispro (IL) in Obese Subjects. Abstract 526, 64th Annual Scientific Sessions, 2004. ,
Pharmacokinetics and Safety of lnsulin Glulisine in Children and Adolescents with Type 1 Diabetes. Abstract 2538, 64th Annual Scientific Sessions, 2004. ,
Safety of lnsulin Glulisine Compared with lnsulin Aspart Administered by Continuous Subcutaneous lnsulin Infusion (CSll) Abstract 15-0R 64th Annual Scientific Sessions, 2004. ,
[LysB3, GluB29] insulin: a novel insulin analog with enhanced ??-cell protective action, Biochemical and Biophysical Research Communications, vol.310, issue.3, pp.852-861, 2003. ,
DOI : 10.1016/j.bbrc.2003.09.090
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use, Diabetes, vol.49, issue.6, pp.999-1005, 2000. ,
DOI : 10.2337/diabetes.49.6.999
Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs, Diabetologia, vol.259, issue.Suppl 2, pp.281-88, 1996. ,
DOI : 10.1007/BF00418343
Effect of Fatty Acids and Selected Drugs on the Albumin Binding of a Long-Acting, Acylated Insulin Analogue, Journal of Pharmaceutical Sciences, vol.86, issue.12, pp.1365-68, 1997. ,
DOI : 10.1021/js9701768
Reduced pharmacokinetic (PK) variability of a navel, long-acting insulin analog (Abstract), Diabetes, vol.48, p.103, 1999. ,
Lantus® et Levemir® deux nouveaux analogues d'insulines à effet prolongé, Paediatrica. Vol, vol.15, issue.4, pp.50-53, 2004. ,
Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin, Diabetologia, vol.42, issue.10, pp.1254-63, 1999. ,
DOI : 10.1007/s001250051301
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use, Diabetes, vol.49, issue.6, pp.999-1005, 2000. ,
DOI : 10.2337/diabetes.49.6.999
Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus, Diabetic Medicine, vol.113, issue.5, pp.371-375, 2000. ,
DOI : 10.1007/s001250051416
Lower and more predictable fasting blood glucose and reduced risk of nocturnal hypoglycaemia with once daily insulin detemir versus NPH in subjects with type 1 diabetes Stand! Efficacy and safety of 6·-month treatment with insulin di;:;temîr in type 1 diabetic patîents on a basal, ln: European Association for the Study of Diabetes 37tl1 Annual Meeting, pp.51-180, 2001. ,
Treatment with insulin detemir allows flexible timing of administration in subjects with type 1 diabetes [abstract]. ln: 1 Bth International Diabetes Federation Gongress Novo Nordisk, 2003. ,
Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304, Diabetic Medicine, vol.39, issue.Suppl. 1, pp.332-338, 1999. ,
DOI : 10.1046/j.1464-5491.1999.00081.x
Treatment with insulin detemir is associated with predictable fasting blood glucose levels and favourable weight development in subjects with type 2 diabetes, Diabetes, vol.52, issue.1, p.120, 2003. ,
lnsulin detemir is associated with more predictable glycaemic contrai and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart, Diabetes Gare, vol.26, issue.3, pp.590-596, 2003. ,
Hirsh: « lnsulin strategies for primary care providers », Clinical diabetes, pp.11-17, 2002. ,
Novel hepatoselective insulin analogues: studies with covalently linked thyroxyl insulin complex in humans, Diabetes Gare, vol.23, pp.1124-1129, 2000. ,
Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial, Metabolism, vol.53, issue.1, pp.54-62, 2004. ,
DOI : 10.1016/j.metabol.2003.07.021
Oral lnsulin: Pharmacokinetics and Pharmacodynamies of Human lnsulin Following Oral Administration of an lnsulin/Delivery Agent Capsule Healthy Volunteers, Diabetes Journal of the American Diabetes Association, vol.51, issue.2, p.48, 2002. ,
Insuline inhalée : un espoir bien inspiré pour les diabétiques? info Respiration, p.21, 2002. ,
Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study, The Lancet, vol.357, issue.9253, pp.357-331, 2001. ,
DOI : 10.1016/S0140-6736(00)03638-2
Time action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin, Diabetes, issue.A10, p.39, 2000. ,
Inhaled Human Insulin Treatment in Patients with Type 2 Diabetes Mellitus, Annals of Internal Medicine, vol.134, issue.3, pp.203-210, 2001. ,
DOI : 10.7326/0003-4819-134-3-200102060-00011
Treatment satisfaction in type 2 diabetes: A comparison between an inhaled insulin regimen and a subcutaneous insulin regimen, Clinical Therapeutics, vol.24, issue.4, pp.552-64, 2002. ,
DOI : 10.1016/S0149-2918(02)85131-1
Treatment Satisfaction With Inhaled Insulin in Patients With Type 1 Diabetes: A randomized controlled trial, Diabetes Care, vol.24, issue.9, pp.1556-1565, 2001. ,
DOI : 10.2337/diacare.24.9.1556
Exubera Phase Ill Study Group Efficacy and safety of inhaled insulin compared to subcutaneous insulin therapy in an intensive insulin regimen in patients with type 1 diabetes: results of 6 month, randomised, European Association for the Study of Diabetes 38 1 h Annual Meeting, 2002. ,
Exubera Phase Ill Study Group Mealtime rapid-acting inhaled insulin improves glycaemic contrai in patients with type 2 diabetes failing combination oral agents: a 3 month, randomised, comparative trial in European Association for the Study of, Diabetes, vol.38, p.111 ,
Efficacy and safety of inhaled insulin compared to subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6 month, randomised, comparative trial in European Association for the Study of Diabetes 38th Annual Meeting, 2002. ,
Pulmonary Insulin Administration Using the AERx?? System: Physiological and Physicochemical Factors Influencing Insulin Effectiveness in Healthy Fasting Subjects, Diabetes Technology & Therapeutics, vol.2, issue.2, pp.185-197, 2000. ,
DOI : 10.1089/15209150050025131
Comparison of in vitro and in vivo efficiencies of a navel unit-dose aerosol generator and a pressurised metered dose inhaler ,
New horizons -Alternative routes fo insulin therapy, Nat Rev Drug Discov, issue.17, pp.529-569, 2002. ,
Pharmacokinetics and pharmacodynamies of pulmonary insulin delivered via the AERx diabetes management system in type 1 diabetics. Diabeto/ogia 43, p.201, 2000. ,
Pharmacokinetics of pulmonary insulin in healthy smokers and non-smokers, Diabetologia, vol.44, p.816, 2001. ,
Pulmonary delivery of insulin using the AERx TM insulin diabetes management system in healthy and asthmatic subjects, Diabetologia, vol.44, p.9, 2001. ,
New nebuliser technology-Aerosol generation by using a vibrating mesh or plate with multiple apertures. Business briefing: long term health care strategies, pp.1-2, 2003. ,
Dose-Response Relationships of lnhaled lnsulin Delivered via the Aerodose lnsulin Inhaler and Subcutaneously lnjected lnsulin in Patients With Type 2 Diabetes, Diabetes Gare, vol.26, pp.2842-2847, 2003. ,
Electronic DPI for insulin, Drug Discovery Today, vol.7, issue.4, pp.213-217, 2002. ,
DOI : 10.1016/S1359-6446(02)02190-6
AIR insulin : complete diabetes therapy via inhalation of fastacting and slow-acting dry powder aerosols, Diabetes, vol.43, issue.1, p.37, 2000. ,
Techosphere insulin: bioavailability and pharmacokinetic properties in healthy volunteers Technosphere/lnsulin--a new approach for effective delivery of human insulin via the pulmonary route, Diabetologia Diabetes Technol Ther, vol.4, issue.15, pp.43589-94, 2000. ,
Long-term efficacy and safety of insulin detemir in subjects with type 1 diabetes. Favorable weight development and risk reduction of nocturnal hypoglycemia [abstract]. ln: American Diabetes Association 62nd Scientific Sessions Novo Nordisk, 2002. ,
Comparison of the Soluble Basal Insulin Analog Insulin Detemir With NPH Insulin: A randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy, Diabetes Care, vol.24, issue.2, pp.296-301, 2001. ,
DOI : 10.2337/diacare.24.2.296
la mise à l'insuline du diabétique noninsulinodependant , www.sante.ujf-grenoble.fr, 2004. ,
Vialettes, mise à l'insuline du diabétique non insulino-dependant, www.alfediam.org consulté en, 2004. ,
24-hour lantus® (insulin glargin (r-DNA origin injection), 2004. ,
Study compares insulin glargine with NPH insulin in children with type 1 diabetes, Adresse URL, 2004. ,
( @Jrrmrnt ~Jr \urr ? . 1 m JH' ~nrn n ùr~ mti. " itrrn flr l.a fomfü\ ~r!T r 1m!H~ Hll'rH ~w l'u1·i'irt hi~i1 µ!,~ummc lt ,
rt lt ?· !ii mmt ~ iiu ta füttu·, mit +n-ufi . : ?i !! hm tu1rr nnmrtcürr t l br n·~1 vn 1.1?r uuu 1 ·ru l ~m:ru1 1. ~c lrit hdul l11n ru 11 ig.m'HI'. niai!i mm??ê !ru 1 ·1?t\lru ~ r l'l1unnr1u. ~ r h' iu·ttb itr ri ~u ~ r11itrh~· rflOEJ:'UH 1 1tL tic tl.l' iunmh1 rutblh?t Ut!l m:r.fiJHl lil.füJbihtf rf llH'! ~ l'tmini i'HHl. "t!i li' m~i l <.rt~ l~ l' t !m htunU · 11 unrn hu : ~ 1 n m1 n m nw h· IH " curHlîUft !i'ai à ultHtï r mr ,
insuline dans l'arsenal thérapeutique du diabète de type 2 et à quel· moment la proposer au patient. D'a1:Jtre part, de présenter les nouvelles insulines, issues de la technologie de l'ADN recombinant, dont la cinétique est plus proche des besoins physiologiques et q1:Ji représente un acquis significatif en termes d'amélioration de l'efticaci, té du traitement et de qualité de ,
Diabète de type 2, Insulinothérapie, nouvelles insulines, nouveaux dispositifs d'administration de l'insuline ,